Enoxaparin in unstable angina/non-ST-segment elevation myocardial infarction: Treatment benefits in prespecified subgroups

Journal of Thrombosis and Thrombolysis

Volumn 12, Issue 3, 2001, Pages 199-206

  Cohen, M ^a   Antman, E M ^b   Gurfinkel, E P ^c   Radley, D ^d  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HOSPITAL UNIVERSITARIO FUNDACIÓN FAVALORO   (Argentina)

^d Aventis Pharmaceuticals   (United States)

Author keywords

Enoxaparin; Heparin; Non ST segment elevation myocardial infarction; Unstable angina

Indexed keywords

ACETYLSALICYLIC ACID; ENOXAPARIN; HEART ENZYME; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ADULT; AGED; ARTICLE; BLOOD CLOT LYSIS; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE MARKER; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG USE; ELECTROCARDIOGRAPHY MONITORING; FEMALE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HOSPITAL ADMISSION; HUMAN; INCIDENCE; INFORMATION PROCESSING; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MORTALITY; MULTIVARIATE ANALYSIS; OUTCOMES RESEARCH; PHASE 3 CLINICAL TRIAL; POPULATION RESEARCH; POPULATION RISK; PREDICTION; PRIORITY JOURNAL; Q WAVE; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; REVASCULARIZATION; RISK MANAGEMENT; SEX DIFFERENCE; SMOKING HABIT; ST SEGMENT ELEVATION; STATISTICAL ANALYSIS; STATISTICAL MODEL; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

ADULT; AGED; ANGINA, UNSTABLE; CLINICAL TRIALS, PHASE III; ELECTROCARDIOGRAPHY; ENOXAPARIN; FEMALE; HEPARIN; HUMANS; MALE; MIDDLE AGED; MODELS, STATISTICAL; MYOCARDIAL INFARCTION; ODDS RATIO; RECURRENCE; RISK FACTORS; THERAPEUTIC EQUIVALENCY; TREATMENT OUTCOME;

EID: 0035728302     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1015259706522     Document Type: Article

References (27)

1. Mechanisms leading to myocardial infarction: Insights from studies of vascular biology
2. Aspirin, heparin or both to treat acute unstable angina
3. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease
4. Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users
5. A comparison of low molecular weight heparin with unfractionated heparin for unstable coronary artery disease
6. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction: Results of the thrombolysis in myocardial infarction (TIMI) 11B trial
7. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis
8. The broad spectrum of unstable angina pectoris and its implications for future controlled trials
9. Risk stratification in unstable angina. Prospective validation of the Braunwald classification
10. Factors associated with failure of medical therapy in patients with unstable angina and non-Q-wave myocardial infarction
11. Risk stratifying acute coronary syndromes: Gradient of risk and benefit
12. Predictors of recurrent ischemic events and death in unstable coronary artery disease after treatment with combination antithrombotic therapy
13. The electrocardiogram predicts one-year outcome of patients with unstable angina and non-Q wave myocardial infarction: Results of the TIMI III Registry ECG Ancillary Study. Thrombolysis in myocardial ischemia
14. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina
15. Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes
16. Emergency room triage of patients with acute chest pain by means of rapid testing for cardiac troponin T or troponin I
17. The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making
18. Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: One-year results of the ESSENCE Study. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q Wave Coronary Events
19. Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: Results from the GUSTO-I trial
20. Predictors of the effect of heparin during cardiac catheterization
21. Heparin kinetics: Variables related to disposition and dosage
22. Influences of sex and smoking habits on anticoagulant activity in low-molecular-weight heparin treatment of unstable coronary artery disease
23. Thrombotic reactant markers in non-ST segment elevation acute coronary syndromes treated with either enoxaparin (low molecular weight heparin) or unfractionated heparin
24. Is early invasive treatment of unstable coronary artery disease equally effective for both women and men? FRISC II Study Group Investigators
25. The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making
26. Comparison of low molecular weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease
27. Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAXIS. (FRAXiparine in Ischaemic Syndromes)